Compare CUBE & ALKS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CUBE | ALKS |
|---|---|---|
| Founded | 2004 | 1987 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.8B | 7.0B |
| IPO Year | 2004 | 2012 |
| Metric | CUBE | ALKS |
|---|---|---|
| Price | $40.47 | $42.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 14 |
| Target Price | ★ $44.00 | $43.43 |
| AVG Volume (30 Days) | 1.7M | ★ 2.0M |
| Earning Date | 04-30-2026 | 05-05-2026 |
| Dividend Yield | ★ 5.34% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | $1,123,110,000.00 | ★ $1,475,899,000.00 |
| Revenue This Year | $0.66 | $24.26 |
| Revenue Next Year | $2.82 | $4.47 |
| P/E Ratio | $111.01 | ★ N/A |
| Revenue Growth | ★ 5.33 | N/A |
| 52 Week Low | $35.09 | $25.17 |
| 52 Week High | $44.13 | $44.57 |
| Indicator | CUBE | ALKS |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 69.90 |
| Support Level | $39.55 | $27.65 |
| Resistance Level | $40.99 | N/A |
| Average True Range (ATR) | 0.76 | 1.47 |
| MACD | -0.02 | 0.39 |
| Stochastic Oscillator | 81.11 | 76.44 |
CubeSmart is a real estate investment trust that acquires, owns, and manages self-storage facilities throughout the United States. The company's real estate portfolio is composed of buildings with numerous enclosed storage areas for both residential and commercial customers to rent mainly on a month-by-month basis. Majority of CubeSmart's facilities are located in Florida, Texas, California, New York, and Illinois. Cumulatively, these states account for both the majority of the square footage in the company's real estate portfolio and the majority of its revenue. The company derives nearly all of its revenue from rental income from tenants utilizing its storage facilities.
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.